{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:58:49Z","timestamp":1774983529117,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7759\/cureus.106216","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:08:49Z","timestamp":1774980529000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Survival: A Single-Center Analysis of Complication Burden, Healthcare Utilization, and Treatment Feasibility in Higher-Risk Myelodysplastic Neoplasms"],"prefix":"10.7759","author":[{"given":"Mihai-Emilian","family":"Lapadat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Stanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina  N","family":"Triantafyllidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca M","family":"Ciobanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta M","family":"Berbec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Negotei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian T","family":"Barta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero G","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023, 98:1307-25. 10.1002\/ajh.26984","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02203-z","article-title":"Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells","volume":"38","author":"van Spronsen MF","year":"2024","unstructured":"van Spronsen MF, Van Gassen S, Duetz C, Westers TM, Saeys Y, van de Loosdrecht AA. Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells. Leukemia. 2024, 38:1365-77. 10.1038\/s41375-024-02203-z","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020\u2606)","volume":"32","author":"Fenaux P","year":"2021","unstructured":"Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020\u2606). Ann Oncol. 2021, 32:142-56. 10.1016\/j.annonc.2020.11.002","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg PL","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al.. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012, 120:2454-65. 10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284946","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kr\u00f6ger N","year":"2025","unstructured":"Kr\u00f6ger N. Treatment of high-risk myelodysplastic syndromes. Haematologica. 2025, 110:339-49. 10.3324\/haematol.2023.284946","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0005","article-title":"Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment","volume":"120","author":"Nachtkamp K","year":"2023","unstructured":"Nachtkamp K, Kobbe G, Gattermann N, Germing U. Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment. Dtsch Arztebl Int. 2023, 120:203-10. 10.3238\/arztebl.m2023.0005","journal-title":"Dtsch Arztebl Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040808","article-title":"Infectious complications in patients with myelodysplastic syndromes: a report from the D\u00fcsseldorf MDS Registry","volume":"16","author":"Kasprzak A","year":"2024","unstructured":"Kasprzak A, Andresen J, Nachtkamp K, et al.. Infectious complications in patients with myelodysplastic syndromes: a report from the D\u00fcsseldorf MDS Registry. Cancers (Basel). 2024, 16:808. 10.3390\/cancers16040808","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286880","article-title":"Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry","volume":"110","author":"Houtman B","year":"2025","unstructured":"Houtman B, Taylor A, Van Marrewijk C, et al.. Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry. Haematologica. 2025, 110:2367-75. 10.3324\/haematol.2024.286880","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14049","article-title":"Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes","volume":"111","author":"Mo A","year":"2023","unstructured":"Mo A, Wood E, Shortt J, Hu E, McQuilten Z. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes. Eur J Haematol. 2023, 111:592-600. 10.1111\/ejh.14049","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.11.036","article-title":"Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis","author":"Gergi M","year":"2026","unstructured":"Gergi M, Sparks A, Zakai NA, Adrianzen-Herrera D. Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis. J Thromb Haemost. 2026, 10.1016\/j.jtha.2025.11.036","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091587","article-title":"Unmet needs and their impact on quality of life and symptoms in myelodysplastic neoplasm patients and caregivers","volume":"17","author":"Cris\u00e0 E","year":"2025","unstructured":"Cris\u00e0 E, Cilloni D, Riva M, et al.. Unmet needs and their impact on quality of life and symptoms in myelodysplastic neoplasm patients and caregivers. Cancers (Basel). 2025, 17:1587. 10.3390\/cancers17091587","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70066","article-title":"Real-world healthcare resource utilisation in patients with higher-risk myelodysplastic syndrome during azacitidine treatment: a population-based cohort study","volume":"6","author":"Brommann SJ","year":"2025","unstructured":"Brommann SJ, Pilgaard L, Jensen JF, Olesen AE, Kristensen DT, Severinsen MT. Real-world healthcare resource utilisation in patients with higher-risk myelodysplastic syndrome during azacitidine treatment: a population-based cohort study. EJHaem. 2025, 6:e70066. 10.1002\/jha2.70066","journal-title":"EJHaem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071333","article-title":"Real-world outcome and prognostic factors in MDS patients treated with azacitidine-a retrospective analysis","volume":"16","author":"Wi\u015bniewski K","year":"2024","unstructured":"Wi\u015bniewski K, Pruszczyk-Matusiak K, Pu\u0142a B, Lech-Mara\u0144da E, G\u00f3ra-Tybor J. Real-world outcome and prognostic factors in MDS patients treated with azacitidine-a retrospective analysis. Cancers (Basel). 2024, 16:1333. 10.3390\/cancers16071333","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.07.004","article-title":"Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes","volume":"61","author":"Czech MM","year":"2024","unstructured":"Czech MM, Schulz E, Mina A, Gea-Banacloche J. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes. Semin Hematol. 2024, 61:348-57. 10.1053\/j.seminhematol.2024.07.004","journal-title":"Semin Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06374-2","article-title":"An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia","volume":"104","author":"Chen X","year":"2025","unstructured":"Chen X, Shukla M, Choi JH. An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia. Ann Hematol. 2025, 104:4319-32. 10.1007\/s00277-025-06374-2","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06421-y","article-title":"Deciphering clinical features and treatment patterns of thrombocytopenic myelodysplastic syndromes","volume":"104","author":"Galli N","year":"2025","unstructured":"Galli N, Pettine L, Croci G, Passamonti F, Barcellini W, Fattizzo B. Deciphering clinical features and treatment patterns of thrombocytopenic myelodysplastic syndromes. Ann Hematol. 2025, 104:3261-9. 10.1007\/s00277-025-06421-y","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16884","article-title":"Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): a retrospective multicenter study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"62","author":"Jouzier C","year":"2022","unstructured":"Jouzier C, Cherait A, Cony-Makhoul P, et al.. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): a retrospective multicenter study by the Groupe Francophone des My\u00e9lodysplasies (GFM). Transfusion. 2022, 62:961-73. 10.1111\/trf.16884","journal-title":"Transfusion"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01416-1","article-title":"MDS-447: a systematic literature review of the economic burden in patients with myelodysplastic syndromes","volume":"22","author":"Kataria A","year":"2022","unstructured":"Kataria A, Jaegerskog E, Jindal R, et al.. MDS-447: a systematic literature review of the economic burden in patients with myelodysplastic syndromes. Clinical Lymphoma, Myeloma and Leukemia. 2022, 22:315-2152. 10.1016\/S2152-2650(22)01416-1","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283661","article-title":"Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"109","author":"Jain AG","year":"2024","unstructured":"Jain AG, Ball S, Aguirre L, et al.. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024, 109:2157-64. 10.3324\/haematol.2023.283661","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2025.11.010","article-title":"Myelodysplastic syndromes and incident cardiovascular disease: a nationwide, real-world cohort study","volume":"11","author":"Aoki H","year":"2025","unstructured":"Aoki H, Suzuki Y, Kaneko H, et al.. Myelodysplastic syndromes and incident cardiovascular disease: a nationwide, real-world cohort study. Can J Cardiol. 2025, 11:10.1016\/j.cjca.2025.11.010","journal-title":"Can J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.911","article-title":"Real-world study of the use of azacitidine in myelodysplasia in Australia","volume":"5","author":"Enjeti A","year":"2024","unstructured":"Enjeti A, Ashraf A, Caillet V, et al.. Real-world study of the use of azacitidine in myelodysplasia in Australia. EJHaem. 2024, 5:527-34. 10.1002\/jha2.911","journal-title":"EJHaem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.008","article-title":"Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes","volume":"24","author":"Rajakumaraswamy N","year":"2024","unstructured":"Rajakumaraswamy N, Gandhi M, Wei AH, et al.. Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2024, 24:260-268.e2. 10.1016\/j.clml.2023.12.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223636","article-title":"When and for whom does intensive care unit admission change the prognosis in oncology?-a scoping review","volume":"17","author":"Codru IR","year":"2025","unstructured":"Codru IR, Vecerzan L. When and for whom does intensive care unit admission change the prognosis in oncology?-a scoping review. Cancers (Basel). 2025, 17:10.3390\/cancers17223636","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475753-beyond-survival-a-single-center-analysis-of-complication-burden-healthcare-utilization-and-treatment-feasibility-in-higher-risk-myelodysplastic-neoplasms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:08:50Z","timestamp":1774980530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475753-beyond-survival-a-single-center-analysis-of-complication-burden-healthcare-utilization-and-treatment-feasibility-in-higher-risk-myelodysplastic-neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.106216","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}